let us OWCP shareholders not forget why this expert in his field was brought on ===>
OWC Pharmaceutical Research Corp Announced Personnel Changes Published: Aug 21, 2018
RAMAT GAN, Israel, Aug. 21, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that as part of the our preparation for Phase II efficacy study (the "Psoriasis Study") of our cannabinoid-based ointment for the treatment of skin diseases, we have appointed Professor Yuval Ramot as a consultant.
- Professor Ramot is the Head of the Psoriasis Clinic at Hadassah - Hebrew University Medical Center in Jerusalem, Israel ("Hadassah") and specializes in Dermatology and Venereology.
- Professor Ramot holds an MD and an MSc degree in Biochemistry from the Hebrew University of Jerusalem, Israel. Following his medical training, he specialized in hair research in the Department of Dermatology at Lübeck University, Germany.
- In March 2016, he joined the Department of Dermatology at Hadassah and the Center for Genetic Diseases of the Skin and Hair, where he focuses on research of genetic skin and hair diseases and toxicology of the skin. His main clinical interest is in inflammatory diseases of the skin.
- He is the director of the psoriasis and hidradenitis suppurativa clinics at Hadassah. He is the recipient of a Minerva Post-doctoral Fellowship and the Young Dermatologist International Achievement Award. He has also co-authored 10 chapters in books and more than 135 articles in peer-reviewed journals.
Mr. Mordechai Bignitz, Chief Executive Officer, commented, "We are continuing to strengthen our clinical research team as we progress with our studies and we are thrilled to have someone of the stature of Professor Ramot joining our team. We are confident that Professor Ramot's knowledge and connections in this field will significantly contribute to the success of our research and our products."
Professor Ramot commented, "I am very pleased to join the OWC team as a consultant and contribute to the research and development of new drugs for inflammatory diseases especially psoriasis, a common and chronic skin disease that has a significant impact on the quality of life of those who suffer from it.
"Development of new and effective drugs for dermatology has been a difficult endeavor and I believe that cannabis-based medical products can provide a breakthrough in providing solutions for a number of debilitating conditions in this field."
The Canadian Securities Exchange, OTC Markets Group court Israeli cannabis, blockchain startups
No Israeli companies are currently traded on the CSE, but following last week’s meetings several companies have started the process, Mr. Carleton said, adding he expects to see the companies listed within four to six months.
News 
Market Data 
Discover 
